To Study the Efficacy and Safety of Sodium Cromoglycate, Lodoxamide and Loteprednol in Treatment of Vernal Keratoconjunctivitis at Tertiary Care Hospital
Vernal keratoconjunctivitis (VKC) is a complex, Th2 cell-mediated inflammatory condition of the ocular surface that primarily affects males, particularly children and young adults. This condition involves an overactivity of immune cells, including mast cells, eosinophils, and Th2 cells, along with increased levels of cytokines, chemokines, and adhesion molecules. The main aim the study is the detect the efficacy of sodium cromoglycate, lodoxamide and loteprednol in treatment of Vernal keratoconjunctivitis (VKC). Methods randomized; comparative study was conducted on patients visiting the OPD at tertiary care hospital. The study included 150 patients diagnosed with VKC (vernal keratoconjunctivitis), patients were divided into three groups based on randomisation. Group A 50 patients treated with sodium cromoglycate Group B 50 patients treated with lodoxamide and group C patients treated with loteprednol, administered twice daily for 8 weeks. The reduction in signs and symptoms in groups was compared. White blood counts were measured for all patients before and after the treatment. Observations and results were systematically tabulated, and data were analysed using SPSS software. An unpaired t-test was used to determine statistical significance between the three groups, with a P-value < 0.05 considered statistically significant. Results: The study population included 150 patients, with 108 (72%) aged 5-10 years and 42 (28%) aged 11-15 years. Among them, 98 (65.3%) were male and 52 (34.7%) female. Shield ulcer was the most common symptom in patients with Vernal keratoconjunctivitis (VKC), occurring in 94.7% of cases, followed by sticky mucous discharge in 88% of patients. Infection was associated with elevated white blood cell count and CRP levels, as well as increases in neutrophils, eosinophils, and CRP. After treatment, improvements were noted in neutrophils, and significant changes were seen in basophils and CRP by the third visit (p = 0.005). Average CRP levels were monitored across all three treatment groups, alongside eosinophil and neutrophil counts. Conclusion for the treatment of vernal keratoconjunctivitis (VKC) mono drug therapy of sodium cromoglycate, lodoxamide and loteprednol shows significant improvement in treatment of Vernal keratoconjunctivitis (VKC).